Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dipen Bhuva

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Biomedical Signal Processing and Control|June 26, 2023
Optimized DEC: An effective cough detection framework using optimal weighted Features-aided deep Ensemble classifier for COVID-19Muhammad Awais, Abhishek Bhuva, Dipen Bhuva, et al.
BMC Cancer|August 18, 2025
A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohortNihanthy D Sreenath, Suresh Pandalanghat, Amul Kapoor, et al.
South Asian Journal of Cancer|December 23, 2020
Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective StudyAmol Patel, Dharmesh Soneji, Harinder Pal Singh, et al.
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Frontiers in Immunology|May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Biomedical Signal Processing and Control|June 26, 2023
Optimized DEC: An effective cough detection framework using optimal weighted Features-aided deep Ensemble classifier for COVID-19Muhammad Awais, Abhishek Bhuva, Dipen Bhuva, et al.
BMC Cancer|August 18, 2025
A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohortNihanthy D Sreenath, Suresh Pandalanghat, Amul Kapoor, et al.
South Asian Journal of Cancer|December 23, 2020
Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective StudyAmol Patel, Dharmesh Soneji, Harinder Pal Singh, et al.
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Frontiers in Immunology|May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
Pageof 2